Articles related to BRAIN CANCER
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
The phase 2 trial provides evidence that dabrafenib combined with trametinib could serve as a more effective and safer first-line treatment option for pediatric low-grade gliomas with BRAF V600 mutations. Evaluate the data to consider how this may influence your treatment protocols.
Oncology, Medical September 25th 2023
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination with Extension of Survival Among Patients with Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
In this phase 3 nonrandomized controlled trial of 331 patients, patients with newly diagnosed glioblastoma (nGBM) receiving autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) had a median OS of 19.3 months from randomization (22.4 months from surgery), while contemporaneous, matched external control patients receiving SOC had a median OS of 16.5 months from randomization; for patients with recurrent glioblastoma (rGBM), the median OS was 13.2 months from relapse in the DCVax-L group vs. 7.8 months in the external control cohort. Both in nGBM and rGBM, significant increases in the long-term tails of the survival curves were seen.
Oncology, Medical November 28th 2022
FDA Committee Unanimously Rejects 131-I-Omburtamab for Neuroblastoma
The FDA Oncologic Drugs Advisory Committee (ODAC) unanimously decided on October 28 that there is insufficient evidence to support the claim that the pediatric oncology drug 131-I-omburtamab improves overall survival. A radiolabeled antibody, 131-I-omburtamab was created to treat central nervous system/leptomeningeal (CNS/LM) metastases in pediatric patients with neuroblastoma.
Oncology, Medical November 7th 2022
Should We Still Be Concerned About Cell Phones and Brain Cancer?
There aren’t as many headlines concerning cell phones and brain cancer today, despite it formerly being a mainstay of frightened online fodder. Have people lost interest and simply unwilling to give up their phones? Have the studies on the topic allayed their concerns? Or is it that people just don’t believe cell phones are one of the numerous cancer hazards? Experts weigh in.
Oncology, Medical October 31st 2022